Esticast Logo
Get In Touch!

Circulating Tumor Cell Diagnostics Market, By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028

  • Published On: Jul, 2019
  • Category: Healthcare
  • Pages: 111
The global Circulating Tumor Cell Diagnosis market size is estimated at 26.9 billion USD with a CAGR of 12.9% during the forecasted period from 2021-2028.

Market Overview

The global Circulating Tumor Cell Diagnosis market size is estimated at 26.9 billion USD with a CAGR of 12.9% during the forecasted period from 2021-2028. Circulating tumor cells (CTCs) are cells that detached from a core tumor and go to other parts in the body across the bloodstream. These cells are employed in analysis of the patient’s blood sample to detect if he/she is suffering from cancer. In addition, CTCs are used to know the disease development and plan of treatment needed for tumor removal. Circulating tumor cells tests can be used to examine several types of cancer such as breast cancer, prostate cancer, colon cancer, etc. The key factor driving the Circulating Tumor Cell Diagnosis market is attributed to increasing prevalence of cancer across the globe. In addition, an ever-increasing demand for minimally invasive diagnostic procedures is expanding this market. Also, uprising demand for precautionary medicine and companion diagnostics is positively impacting the market size. Additionally, several prospective uses in pretreatment, pre-diagnosis, etc. provide profitable development openings to companies concerned in the development of CTC products. Moreover, research institutes are involved in accomplishments intended at budding CTC-based tests to progress cancer diagnosis concerning efficacy and pace. Furthermore, rise in awareness regarding cancer along with improving healthcare infrastructure in emerging economies is projected to fuel the demand for Circulating Tumor Cell Diagnosis. On the other hand, one of the major factors restraining the Circulating Tumor Cell Diagnosis market is its high cost. In addition, another notable factor to hinder this market is inadequate applicability of CTC in uncommon cancers. Also, lack of skilled healthcare personnel in emerging nations is expected to limit the market growth. Besides, the outburst of COVID-19 pandemic is undesirably affecting the growth of this market owing to lockdowns laid in nations, fear of visiting hospitals, priority spending by consumers, and so on.

Market Driver

The cancer burden is increasing, and thus, cancer therapies must be modified globally. The increasing incidence of cancer is boosting the global Circulating Tumor Cell Diagnostics market. For instance, according to the World Health Organization, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Around 70% of deaths from cancer occur in low and middle-income countries. The most common cancers are Lung cancer, which accounts for 2.09 million death cases worldwide. Breast cancer accounts for 2.09 million death cases. Colorectal cancer accounts for 1.80 million death cases. Prostate cancer accounts for 1.28 million death cases. Skin cancer accounts for 1.04 million death cases. Stomach cancer accounts for 1.03 million death cases globally. The increasing funding for circulating tumor cell research activities is boosting the global Circulating Tumor Cell market. For instance, April 25, 2019, EMV Capital have invested in Vortex Biosciences, to accelerate the company’s development. The new funding is to improve Cancer detection and therapy by providing the best CTC sample workflow from a standard tube of blood. CTC investigations and new research on single cell drug testing methods.  Moreover, on June 15, 2017, CellMax Life, the precision cancer testing company, has received USD 760,846 from the Taiwan Government Industrial Development Bureau (IDB) Ministry of Economic Affairs. CellMax Life will use the fund to accelerate the automation and worldwide commercialization of its proven early cancer detection circulating tumor cell (CTC) proprietary CellMax CMxTM platform. Additionally, on July 26, 2016, CellMax Life, has raised USD 9 million in funding. The company plans to use the money to bring a variety of tests based on the detection of germline cancer risk mutations, circulating tumor cells, circulating tumor DNA, and epigenetics in the markers, with the aim of moving cancer care away from a focus on "intractable late-stages" toward detection and effective treatment at earlier stages.

Market Restraint

The rare occurrence of circulating tumor cells (CTC) might hamper the global circulating tumor cells market. CTCs are rare, occurring at a rate of one cell per 106 or 107 leucocytes in the human blood. The rarity and molecular and phenotypical heterogeneity of CTCs make their detection highly difficult and although multiple technologies have been developed

Segment Analysis

Based on type, the global Circulating Tumor Cell Diagnostics market is broadly segmented as CTC Enrichment, CTC Detection, and CTC Analysis. In 2018 CTC Detection is the dominant segment, and it accounts for approximately 40% of the market. Circulating Tumor Cell (CTC) detection is accomplished based on physical properties of the cell, including density and size as well as immune and cell-surface electrical properties. CTC detection is a crucial tool to fight against cancer. The CellSearch by Veridex has been cleared for clinical use in breast, colorectal, and prostate cancer patients. It is an automated system for CTC detection; it was the first US FDA-approved diagnostic test to automatically identify and count CTCs in the blood sample. This method enriches cells using a magnetic ferrofluid containing antibodies against epithelial cell adhesion molecule (EpCAM). The clinical trials for Circulating Tumor Cell (CTC) Detection are boosting the global Circulating Tumor Cell Diagnostics market. For instance, in May 30, 2018, CellMax Life, a leading cancer diagnostics company enabling early cancer detection with affordable non-invasive blood tests, have introduced Zenith, a U.S. clinical study for its circulating tumor cell (CTC) blood test, which can transform the way colorectal cancer is detected, enabling diagnosis at its earliest, most treatable stages. Circulating Tumor Cell Diagnostics Market -by type 2018

Regional Analysis

The global Circulating Tumor Cell Diagnostics market is segmented into North America, Europe, China, Japan, ROW. North America is dominating the global Circulating Tumor Cell Diagnostics market, due to the growing incidence of cancer in the U.S. For instance, According to National Cancer Institute, in 2018, around 1,735,350 new cases of cancer have been diagnosed in the United States and 609,640 people have died from the disease. In 2016, there were 15.5 million cancer cases in the United States. The number of cancer cases is expected to increase to 20.3 million by 2026. The clinical trials for Circulating Tumor Cell (CTC) Detection is boosting the North America Circulating Tumor Cell Diagnostics market. For instance, on May 23, 2018, TRACON Pharmaceuticals a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, have introduced new circulating tumor cell data from ongoing pivotal Phase 3 TAPPAS trial of TRC105 and Votrient in patients with angiosarcoma. The North America Circulating Tumor Cell Diagnostics market size was XX million USD in 2018, and it will be 5,992.6 million USD in 2025, with a CAGR 16.6% from 2019 to 2025. Europe is the second largest market for Circulating Tumor Cell Diagnostics in 2018, due to the growing incidence of cancer in the European region. For instance, according to Cancer Research UK, there are around 363,000 new cancer cases in the UK every year, that's more than 990 every day (2014-2016). In 2016, there were around 178,000 female cancer cases, and 185,000 male cancer cases in the U.K. In 2016, there were around 385,000 new cases of cancer were recorded in France.

Competitive Analysis

The major players include Biocept inc., Epic Scicences, Inc., Fluxion Biosciences, Inc., Greiner Bio-one GmbH, Apocell Inc, Creatv Microtech, Inc., Ikonisys, Inc., Rarecell Diagnostics, Qiagen Adnagen, Screencell Silicon Biosystems, and Advanced Cell Diagnostics (bio-techne). The strategic collaboration between companies for increasing research activities is boosting the global Circulating Tumor Cell Diagnostics market. For instance, November 4, 2018, CellMax has partnered with IncellDx on the development and marketing of circulating tumor cell tests for personalized therapy selection and monitoring across multiple solid tumors and indications, combining IncellDx's proprietary BioINK microfluidic reagents and CellMax's CTC isolation technology. Moreover, September 26, 2016, Cancer Genetics, Inc., have entered into a strategic alliance and partnership with ApoCell, the developer of ApoStream, a breakthrough, high-performance technology to detect, isolate and capture circulating tumor cells (CTC) and other rare cells without the need of labels or antibodies. ApoCell is a spin-out of globally recognized, University of Texas MD Anderson Cancer Center, and licenses key technology used in ApoStream from MD Anderson Cancer Center.

Global Circulating Tumor Cell Diagnostics Market

  • Consumption by Regions
    • North America
    • Europe
    • China
    • Japan
    • Rest of the World
  • Segment by Type
    • CTC Enrichment
    • CTC Detection
    • CTC Analysis
  • Segment by Application
    • Tumorigenesis Research
    • EMT Biomarkers Development
    • Cancer Stem Cell Research
    • Others

Table of Contents 1 Circulating Tumor Cell Diagnostics Market Overview 1.1 Product Overview and Scope of Circulating Tumor Cell Diagnostics 1.2 Circulating Tumor Cell Diagnostics Segment by Types 1.2.1 Global Circulating Tumor Cell Diagnostics Sales Growth Rate Comparison by Types (2014-2025) 1.2.2 CTC Enrichment 1.2.3 CTC Detection 1.2.4 CTC Analysis 1.3 Circulating Tumor Cell Diagnostics Segment by Applications 1.3.1 Global Circulating Tumor Cell Diagnostics Sales Comparison by Applications (2014-2025) 1.3.2 Tumorigenesis Research 1.3.3 EMT Biomarkers Development 1.3.4 Cancer Stem Cell Research 1.3.5 Others 1.4 Global Circulating Tumor Cell Diagnostics Market by Regions 1.4.1 Global Circulating Tumor Cell Diagnostics Market Size by Regions 1.4.2 North America Circulating Tumor Cell Diagnostics Status and Prospect (2014-2025) 1.4.3 Europe Circulating Tumor Cell Diagnostics Status and Prospect (2014-2025) 1.4.4 China Circulating Tumor Cell Diagnostics Status and Prospect (2014-2025) 1.4.5 Japan Circulating Tumor Cell Diagnostics Status and Prospect (2014-2025) 1.5 Global Circulating Tumor Cell Diagnostics Market Size 1.5.1 Global Circulating Tumor Cell Diagnostics Revenue (2014-2025) 1.5.2 Global Circulating Tumor Cell Diagnostics Sales (2014-2025) 2 Global Circulating Tumor Cell Diagnostics Market Competition by Manufacturers 2.1 Global Circulating Tumor Cell Diagnostics Sales Market Share by Manufacturers (2014-2019) 2.2 Global Circulating Tumor Cell Diagnostics Revenue Market Share by Manufacturers (2014-2019) 2.3 Global Circulating Tumor Cell Diagnostics Average Price by Manufacturers (2014-2019) 2.4 Manufacturers Circulating Tumor Cell Diagnostics Manufacturing Sites, Area Served, Product Types 2.5 Circulating Tumor Cell Diagnostics Market Competitive Situation and Trends 2.5.1 Circulating Tumor Cell Diagnostics Market Concentration Rate 2.5.2 Circulating Tumor Cell Diagnostics Market Share of Top 5 and Top 10 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global Circulating Tumor Cell Diagnostics Sales by Regions (2014-2019) 3.1 Global Circulating Tumor Cell Diagnostics Sales Market Share by Regions 3.2 Global Circulating Tumor Cell Diagnostics Revenue Market Share by Regions (2014-2019) 3.3 Global Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 3.4 North America Circulating Tumor Cell Diagnostics Sales 3.4.1 North America Circulating Tumor Cell Diagnostics Sales Growth Rate (2014-2019) 3.4.2 North America Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 3.5 Europe Circulating Tumor Cell Diagnostics Sales 3.5.1 Europe Circulating Tumor Cell Diagnostics Sales Growth Rate (2014-2019) 3.5.2 Europe Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 3.6 China Circulating Tumor Cell Diagnostics Sales (2014-2019) 3.6.1 China Circulating Tumor Cell Diagnostics Sales Growth Rate (2014-2019) 3.6.2 China Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 3.7 Japan Circulating Tumor Cell Diagnostics Sales (2014-2019) 3.7.1 Japan Circulating Tumor Cell Diagnostics Sales Growth Rate (2014-2019) 3.7.2 Japan Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 4 Global Circulating Tumor Cell Diagnostics Sales, Revenue, Price Trend by Types 4.1 Global Circulating Tumor Cell Diagnostics Sales Market Share by Types (2014-2019) 4.2 Global Circulating Tumor Cell Diagnostics Revenue Market Share by Types (2014-2019) 4.3 Global Circulating Tumor Cell Diagnostics Price by Type (2014-2019) 4.4 Global Circulating Tumor Cell Diagnostics Sales Growth by Type (2014-2019) 5 Global Circulating Tumor Cell Diagnostics Market Analysis by Applications 5.1 Global Circulating Tumor Cell Diagnostics Sales Market Share by Applications (2014-2019) 5.2 Global Circulating Tumor Cell Diagnostics Consumption Growth Rate by Applications (2014-2019) 6 Company Profiles and Key Figures in Circulating Tumor Cell Diagnostics Business 6.1 Janssen Diagnostics 6.1.1 Janssen Diagnostics Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.1.2 Janssen Diagnostics Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.1.4 Janssen Diagnostics Main Business and Markets Served 6.2 Advanced Cell Diagnostics 6.2.1 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.2.2 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.2.4 Advanced Cell Diagnostics Main Business and Markets Served 6.3 Aviva Biosciences 6.3.1 Aviva Biosciences Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.3.2 Aviva Biosciences Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.3.4 Aviva Biosciences Main Business and Markets Served 6.4 Biocept Inc 6.4.1 Biocept Inc Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.4.2 Biocept Inc Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.4.4 Biocept Inc Main Business and Markets Served 6.5 Biofluidica, Inc. 6.5.1 Biofluidica, Inc. Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.5.2 Biofluidica, Inc. Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.5.3 Biofluidica, Inc. Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.5.4 Biofluidica, Inc. Main Business and Markets Served 6.6 CellTraffix, Inc. 6.6.1 CellTraffix, Inc. Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.6.2 CellTraffix Inc. Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.6.3 CellTraffi, Inc. Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.6.4 CellTraffix, Inc. Main Business and Markets Served 6.7 Clearbridge BioMedics Pte Ltd 6.7.1 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.7.2 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.7.4 Clearbridge BioMedics Pte Ltd Main Business and Markets Served 6.8 Epic Sciences Inc. 6.8.1 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.8.2 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.8.4 Epic Sciences Inc. Main Business and Markets Served 6.9 Fluxion Biosciences Inc. 6.9.1 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.9.2 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.9.4 Fluxion Biosciences Inc. Main Business and Markets Served 6.10 ScreenCell 6.10.1 ScreenCell Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.10.2 ScreenCell Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.10.3 ScreenCell Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.10.4 ScreenCell Main Business and Markets Served 6.11 Silicon Biosystems 6.11.1 Silicon Biosystems Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.11.2 Silicon Biosystems Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.11.4 Silicon Biosystems Main Business and Markets Served 6.12 Sysmex Corporation 6.12.1 Sysmex Corporation Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.12.2 Sysmex Corporation Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.12.4 Sysmex Corporation Main Business and Markets Served 6.13 Greiner Bio-One GmbH 6.13.1 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.13.2 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.13.4 Greiner Bio-One GmbH Main Business and Markets Served 6.14 AdnaGen AG 6.14.1 AdnaGen AG Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.14.2 AdnaGen AG Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.14.4 AdnaGen AG Main Business and Markets Served 6.15 Apocell Inc 6.15.1 Apocell Inc Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.15.2 Apocell Inc Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.15.4 Apocell Inc Main Business and Markets Served 6.16 Biocep Ltd 6.16.1 Biocep Ltd Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.16.2 Biocep Ltd Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.16.4 Biocep Ltd Main Business and Markets Served 6.17 Canopus Bioscience Ltd 6.17.1 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.17.2 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.17.4 Canopus Bioscience Ltd Main Business and Markets Served 6.18 Creatv Microtech Inc 6.18.1 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.18.2 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.18.4 Creatv Microtech Inc Main Business and Markets Served 6.19 Ikonisys Inc 6.19.1 Ikonisys Inc Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.19.2 Ikonisys Inc Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.19.4 Ikonisys Inc Main Business and Markets Served 6.20 IV Diagnostics Inc 6.20.1 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.20.2 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.20.4 IV Diagnostics Inc Main Business and Markets Served 6.21 Miltenyi Biotech GmbH 6.21.1 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.21.2 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.21.4 Miltenyi Biotech GmbH Main Business and Markets Served 6.22 Nanostring Technologies Inc 6.22.1 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.22.2 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.22.4 Nanostring Technologies Inc Main Business and Markets Served 6.23 Rarecells Diagnostics. 6.23.1 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.23.2 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.23.4 Rarecells Diagnostics. Main Business and Markets Served 6.24 Vitatex Inc 6.24.1 Vitatex Inc Circulating Tumor Cell Diagnostics Manufacturing Sites and Area Served 6.24.2 Vitatex Inc Circulating Tumor Cell Diagnostics Product Introduction, Application and Specification 6.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Sales and Revenue (2014-2019) 6.24.4 Vitatex Inc Main Business and Markets Served 7 Circulating Tumor Cell Diagnostics Manufacturing Cost Analysis 7.1 Circulating Tumor Cell Diagnostics Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Raw Materials Price Trend 7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Circulating Tumor Cell Diagnostics 7.4 Circulating Tumor Cell Diagnostics Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Circulating Tumor Cell Diagnostics Distributors List 8.3 Circulating Tumor Cell Diagnostics Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.4 Challenges 9.4 Porter's Five Forces Analysis 10 Global Circulating Tumor Cell Diagnostics Market Forecast 10.1 Global Circulating Tumor Cell Diagnostics Sales, Revenue Forecast 10.1.1 Global Circulating Tumor Cell Diagnostics Sales Growth Rate Forecast (2019-2025) 10.1.2 Global Circulating Tumor Cell Diagnostics Revenue and Growth Rate Forecast (2019-2025) 10.1.3 Global Circulating Tumor Cell Diagnostics Price and Trend Forecast (2019-2025) 10.2 Global Circulating Tumor Cell Diagnostics Sales Forecast by Regions (2019-2025) 10.2.1 North America Circulating Tumor Cell Diagnostics Sales, Revenue Forecast (2019-2025) 10.2.2 Europe Circulating Tumor Cell Diagnostics Sales, Revenue Forecast (2019-2025) 10.2.3 China Circulating Tumor Cell Diagnostics Sales, Revenue Forecast (2019-2025) 10.2.4 Japan Circulating Tumor Cell Diagnostics Sales, Revenue Forecast (2019-2025) 10.3 Global Circulating Tumor Cell Diagnostics Sales, Revenue and Price Forecast by Type (2019-2025) 10.4 Global Circulating Tumor Cell Diagnostics Consumption Forecast by Application (2019-2025) 11 Research Findings and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

  • The following manufacturers are covered:
    • Biocept in
    • Epic Scicences, Inc.
    • Fluxion Biosciences, Inc.
    • Greiner Bio-one GmbH
    • Apocell Inc
    • Creatv Microtech, Inc.
    • Ikonisys, Inc.
    • Rarecell Diagnostics
    • Qiagen Adnagen
    • Screencell Silicon Biosystems
    • Advanced Cell Diagnostics (bio-techne)

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS

Esticast Logo

CORPORATE OFFICE

location  (US)

1055 West 7th Street, Los Angeles, CA 90017 (P) US

phone  +1-213-262-0704
location  (APAC Address)

Office No. 407, Navale Icon IT Park, Near Navale Bridge, Narhe, Pune, Maharashtra 411041

phone  +91-959-503-5024

COMPANY

SECURE ONLINE PAYMENTS

  • visa
  • mastercard
  • amex
  • discover

FOLLOW US

  • facebook
  • linkedin
  • phone
  • youtube
© 2022 | All Rights Reserved by Esticast Research & Consulting